Small Pharma (acquired by Cybin)

UK-based Small Pharma is focused on developing psychedelic-assisted psychotherapies based on DMT, deuterium-enriched tryptamine compounds, and ketamine. The company is focused on treating depression and intends to develop therapies for other mental health conditions as well. 

In December 2020, Small Pharma got approval for the world’s first clinical trial using DMT which began in January 2021. The company’s pipeline includes; 1) SPL026, an intravenous (IV) N,N-dimethyltryptamine (DMT) therapy which had completed Phase 2a clinical trial, 2) SPL028, a deuterated DMT in Phase 1 clinical studies, and 3) SPL029, an oral trytamine series in preclinical clinical stage. Further as of January 2023 , the company had 14 granted patents, with over 90 psychedelic and non-psychedelic patent applications pending. 

Key Customers and Partnerships

Small Pharma has established collaborations with academic institutions including, the Imperial College London’s Centre for Psychedelic Research, and the University of Cambridge. In November 2022, the company collaborated with University College London to provide SPL026 for a neuroplasticity brain-imaging study. 

Funding and Financials

The company commenced trading on the over-the-counter markets in May 2021 under the ticker symbol “DMT”.